Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proximod PK/PD in Healthy Subjects
NCT06361186Phase 1Completed
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Placebo with Proximod (2 arms). Primary endpoints: Peak Plasma Concentration up to 64 days, Time to Peak Plasma Concentration up to 64 days and 3 more. Started Sep 2017; status: completed.
02
Drugs
proximod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06361186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361186.